The evidence is also strong that these medications decrease the risk of heart disease -- both in people with and without ...

NIH researchers have identified the intracellular signalling pathways through which semaglutide and other GLP-1 receptor agonists induce weight loss, revealing why patient responses vary and treatment ...

Learn how to transition from injectable GLP-1s to oral options like Wegovy and Foundayo, with expert advice on dosing, side ...

Studies to be presented at the 2026 ASCO Annual Meeting examine GLP-1 receptor agonists in relation to cancer progression, ...

GLP-1 drugs commonly used for weight loss and diabetes decreased the risk of cancer spreading in patients with several ...

Doctronic reports that Foundayo, an oral GLP-1 for diabetes, shows promise but lacks long-term safety data beyond 68 weeks; ...

A new study shows oral GLP-1 drugs suppress hedonic eating through a deep-brain reward circuit linked to dopamine release, potentially extending their use beyond weight loss.

Why GLP-1 drugs like semaglutide and tirzepatide deliver different weight loss results for different people, and why ...

New NIH research reveals that semaglutide sparks different responses inside appetite-controlling brain cells, offering fresh insight into why GLP-1 weight-loss drugs don’t work the same for everyone.

Ozempic was supposed to be a gut story. Then Allison Shapiro looked at the brain scans. An assistant professor at the ...

Meena Bansal, MD, discusses the evolving MASH pipeline and why precision phenotyping, biomarkers, and cardiovascular outcomes ...

GLP-1 therapies help control blood sugar. Beyond this, research shows that these medications can reduce the risk of major ...